New immunosuppressive drugs: An update

Current Opinion in Urology

Volumn 11, Issue 2, 2001, Pages 143-151

  Pohanka, Erich ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AZATHIOPRINE; BREQUINAR; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; EVEROLIMUS; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; ISOXAZOLE DERIVATIVE; LEFLUNOMIDE; MALONONITRILAMIDE; MERCAPTOPURINE; MIZORIBINE; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS; VITAMIN D DERIVATIVE;

HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW;

ADRENAL CORTEX HORMONES; ALKYLATING AGENTS; CALCINEURIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PROPYLENE GLYCOLS; PURINES; PYRIMIDINES; SIROLIMUS; SPHINGOSINE; VITAMIN D;

EID: 0035114702     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200103000-00004     Document Type: Review

References (139)

1. Inhaled glucocorticoids for asthma
2. Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis
3. Strategies to reduce or replace steroid dosing
4. Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression
5. Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression
6. Steroid withdrawal in liver transplantation: Benefits, risks, and unanswered questions
7. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen
8. ANCA-associated crescentic glomerulonephritis with mesangial IgA deposits
9. Vasculitis: Clinical approach, pathophysiology and treatment
10. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation
11. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation
12. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection
13. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study Group
14. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation
15. Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation
16. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease
17. Cyclosporin and tacrolimus: Their use in a routine clinical setting for scleroderma
18. Applications of tacrolimus for the treatment of skin disorders
19. Mechanisms of action of cyclosporine
20. T lymphocyte activation signals for interleukin-2 production involve activation of MKK6-p38 and MKK7-SAPK/JNK signaling pathways sensitive to cyclosporin A
21. The side-effects of ciclosporine-A and tacrolimus
22. The metabolic effects of cyclosporin and tacrolimus
23. Diabetes mellitus and islet cell specific autoimmunity as adverse effects of immunsuppressive therapy by FK506/tacrolimus
24. Mechanisms of nephrotoxicity
25. Nephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future
26. Immunosuppressant-induced nephropathy. Pathophysiology, incidence and management
27. The differential diagnosis between rejection and cyclosporine toxicity
28. Cyclosporine-associated end-stage nephropathy after cardiac transplantation: Incidence and progression
29. Risks and costs of end-stage renal disease after heart transplantation
30. Chronic renal failure following liver transplantation: A retrospective analysis
31. Endothelin in organ transplantation
32. Endothelial dysfunction in renal transplant recipients maintained on cyclosporine
33. Inhibition of endothelinconverting enzyme attenuates transplant vasculopathy and rejection in rat cardiac allografts
34. Sodium depletion enhances fibrosis and the expression of TGF-beta1 and matrix proteins in experimental chronic cyclosporine nephropathy
35. In vivo hyperexpression of transforming growth factor-beta1 in mice: Stimulation by cyclosporine
36. In vivo expression of transforming growth factor-beta1 in humans: Stimulation by cyclosporine
37. Transforming growth factor (TGF)-beta mimics and anti-TGF-beta antibody abrogates the in vivo effects of cyclosporine: Demonstration of a direct role of TGF-beta in immunosuppression and nephrotoxicity of cyclosporine
38. Cyclosporine-induced interstitial fibrosis and arteriolar TGF-beta expression with preserved renal blood flow
39. The role of transforming growth factor beta in chronic renal allograft nephropathy
40. Mechanism of fibrosis in experimental tacrolimus nephrotoxicity
41. Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells
42. TGF-beta expression in renal transplant biopsies: A comparative study between cyclosporin-A and tacrolimus
43. Differential effects of cyclosporin A and tacrolimus on the production of TGF-beta: Implications for the development of obliterative bronchiolitis after lung transplantation
44. Cyclosporine induces cancer progression by a cell-autonomous mechanism
45. Role of angiotensin II in the expression and regulation of transforming growth factor-beta in obstructive nephropathy
46. Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: Role of the renin-angiotensin system
47. Targeting TGF-beta overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade
48. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II
49. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells
50. Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy
51. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis
52. The effects of prolonged angiotensinconverting enzyme inhibition on excretory kidney function and proteinuria in renal allograft recipients with chronic progressive transplant failure
53. Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy
54. Can antibody prophylaxis allow sparing of other immunosuppressives?
55. Progress with cyclosporine-sparing regimens
56. Which calcineurin inhibitor is preferred in renal transplantation: Tacrolimus or cyclosporine?
57. Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation: A report of the U.S. multicenter liver study group
58. Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients
59. Conversion to neoral for neurotoxicity after primary adult liver transplantation under tacrolimus
60. Posttransplant hemolytic uremic syndrome in adult retransplanted kidney graft recipients: Advantage of FK506 therapy?
61. Conversion of renal transplant recipients from cyclosporin (neoral) to tacrolimus (prograf) for haemolytic uraemic syndrome
62. Haemolytic uraemic syndrome (HUS) during treatment with cyclosporin A after renal transplantation - Is tacrolimus the answer?
63. Hemolytic uremic syndrome in small-bowel transplant recipients: The first two case reports
64. Successful use of cyclosporine in a lung transplant recipient with tacrolimus-associated hemolytic uremic syndrome
65. Cyclosporine-induced hemolytic uremic syndrome and hemorrhagic colitis following renal transplantation
66. Tacrolimus-induced hemolytic uremic syndrome and end-stage renal failure after liver transplantation
67. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety
68. Mycophenolate mofetil and its mechanisms of action
69. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection
70. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients
71. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
72. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients
73. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients
74. The use of mycophenolate mofetil in transplant recipients
75. Non-transplant uses of mycophenolate mofetil
76. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection
77. Steroid withdrawal in pancreas transplant recipients
78. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil
79. Nephrotoxicity of calcineurin inhibitors: New therapeutic approaches
80. Conversion to mycophenolate mofetil in conjunction with stepwise withdrawal of cyclosporine in stable renal transplant recipients
81. Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and lowdose cyclosporine
82. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction
83. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients
84. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: A cross-sectional study
85. Pharmacokinetics of FK 506 and mycophenolic acid after the administration of a FK 506-based regimen in combination with mycophenolate mofetil in kidney transplantation
86. Long-term results in mizoribinetreated renal transplant recipients: A prospective, randomized trial of mizoribine and azathioprine under cyclosporine-based immunosuppression
87. Long-term open-trial of mizoribine with prednisolone in 24 patients with multiple sclerosis: Safety, clinical and magnetic resonance imaging outcome
88. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome
89. The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors
90. Recombinant human granulocyte colony-stimulating factor after kidney transplantation: A retrospective analysis to evaluate the benefit or risk of immunostimulation
91. Mechanism of action for leflunomide in rheumatoid arthritis
92. Leflunomide: An immunomodulatory agent for the treatment of rheumatoid arthritis
93. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial
94. Function and health-related quality of life: Results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis
95. The use of leflunomide in the treatment of rheumatoid arthritis: An experimental and clinical review
96. Malononitrilamides inhibit T- and B-cell responsiveness in different species
97. Disease-modifying activity of malononitrilamides, derivatives of leflunomide's active metabolite, on models of rheumatoid arthritis
98. Coadministration of malononitrilamides and tacrolimus induces tolerance in a rat skin allograft model
99. Brequinar in combination with cyclosporine a inhibits islet xenograft rejection for up to 24 days: A study in the pig-to-rat model
100. Brequinar and brequinar analogues in rat allo- and xenotransplantation
101. Side effects of brequinar and brequinar analogues, in combination with cyclosporine, in the rat
102. Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus
103. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: A phase II trial
104. Sirolimus, a new, potent immunosuppressive agent
105. Sirolimus: Continuing the evolution of transplant immunosuppression
106. Therapeutic drug monitoring of sirolimus: Correlations with efficacy and toxicity
107. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study
108. Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey
109. Sirolimus-tacrolimus combination immunosuppression
110. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine
111. SDZ RAD, a new rapamycin derivative: Synergism with cyclosporine
112. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats
113. Suppression of acute rejection in allogeneic rat lung transplantation: A study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine
114. Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation
115. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients
116. A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients
117. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts
118. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders
119. A novel immunosuppressant, FTY720, induces peripheral lymphodepletion of both T- and B cells and immunosuppression in baboons
120. Analysis of the mode of action of a novel immunosuppressant FTY720 in mice
121. Immunosuppressant FTY720 induces apoptosis by direct induction of permeability transition and release of cytochrome c from mitochondria
122. Immunosuppressant FTY720 inhibits thymocyte emigration
123. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory
124. FTY720 blocks allograft rejection by homing of lymphocytes in vivo
125. The FTY720 story
126. FTY720: A novel transplantation drug that modulates lymphocyte traffic rather than activation
127. Effect of FTY720, a novel immunosuppressant, on adjuvant- and collagen-induced arthritis in rats
128. Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats
129. FTY720 prevents development of experimental autoimmune myocarditis through reduction of circulating lymphocytes
130. The significance of timing of FTY720 administration on the immunosuppressive effect to prolong rat skin allograft survival
131. Prolongation of canine liver allograft survival by a novel immunosuppressant, FTY720: Effect of monotherapy and combined treatment with conventional drugs
132. Immunosuppressive therapy using FTY720 combined with tacrolimus in rat liver transplantation
133. FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation
134. The peripheral lymphocyte count predicts graft survival in DA to Lewis heterotopic heart transplantation treated with FTY720 and SDZ RAD
135. Prevention of graft vessel disease by combined FTY720/cyclosporine. A treatment in a rat carotid artery transplantation model
136. Transcriptional repression of the interleukin-2 gene by vitamin D-3: Direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor
137. Nuclear factor of activated T cells (NFAT) as a molecular target for 1 alpha, 25-dihydroxyvitamin D-3-mediated effects
138. Analogs of 1,25-dihydroxyvitamin D-3 as dose-reducing agents for classical immunosuppressants
139. Immunosuppressive strategies in transplantation